NTRK1 and neoplasm: While sorafenib targets mainly the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, a complementary synergetic action of crocin may occur through other mechanisms including the interaction with telomeric quadruplex sequences and down regulation of hTERT expression, resulting in a decreased telomerase activity of HepG2 cells [33].